The present invention provides a compound having the structure:##STR1## wherein X, Y, and Z are independently H, Cl, Br, F,OCH.sub.3, I, or an alkyl group having 1 to 6 carbon atoms; and Ris ##STR2## wherein n is 0 to 6, X' and Y' are independently H, Cl,F, CH.sub.3, C.sub.2 H.sub.5, C.sub.3 H.sub.7, C.sub.4 H.sub.9,OCH.sub.3, OH, CF.sub.3, OCF.sub.3, NO.sub.2, NH.sub.2,N(CH.sub.3).sub.2, NHCOCH.sub.3, NCS, NHCOCH.sub.2 Br, or N.sub.3,and (CH.sub.2).sub.n, if present, may be substituted with OH,OCH.sub.3, or an alkyl or alkenyl group having 1 to 3 carbon atoms.The present invention also provides a pharmaceutical compositioncomprising the compound above and a pharmaceutically acceptablecarrier. The present invention further provides a method fortreating a disease characterized by a dopamine deficiency whichcomprises administering to a subject in need of such treatment anamount of the pharmaceutical composition above effective to treatthe disease.
Selective inhibitors of biogenic amine transporters
Rothman, R., Carroll, F., Blough, B., & Mascarella, S. (1998). IPC No. U.S. Selective inhibitors of biogenic amine transporters. (U.S. Patent No. 5747503).